Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Changhoon Yoo
With
Oncocross Co. Ltd.
CytoGen, Inc.
Age
19–79
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Adults of age ≥ 19 and \< 80 years
2. A patient who meets any of the following criteria at the time of screening or before, and who is scheduled to receive chemotherapy with modified FOLFIRINOX for the first time after screening
* Locally advanced inoperable pancreatic cancer
* Metastatic pancreatic cancer
3. One or more measurable lesions by RECIST v 1.1
4. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 pr 1
5. Estimated life expectancy of at least 12 weeks or more at the discretion of the investigator
You may not be if
1. History of major surgery within 4 weeks at the time of screening
2. Symptomatic, uncontrolled brain metastasis or meningeal carcinomatosis
3. History of malignancy within 5 years at the time of screening
4. History of human immunodeficiency virus (HIV) or active hepatitis
5. Active infection requiring systemic antibiotic therapy
6. Patients who have maculopathy or are receiving treatment for corneal or retinal disease, or under follow-up
7. History of acute or subacute intestinal obstruction or paralytic ileus, or a history of chronic diarrhea considered clinically significant at the discretion of the investigator
8. Serious neurological, psychiatric condition including drug abuse or alcoholism, which would prevent the subject from participating in the study
9. Patients with any condition who are considered unsuitable for participation in the study in the judgment of the investigator
Clareo Health | Hydroxychloroquine and Chlorphenesin Carbamate in Combination With mFOLFIRINOX in Pancreatic Cancer
